Search

Search Constraints

You searched for: Author/Creator Talarn, C.

Search Results

1. 20‐year follow‐up of Hodgkin lymphoma: Predictors of survival and secondary malignancies. (June 2017)

2. 90 INTENSIVE CHEMOTHERAPY VERSUS NO INTENSIVE TREATMENT IN HIGH RISK MYELODYSPLASTYC SYNDROME (MDS) NO-HSCT CANDIDATES. (April 2015)

3. Response to Azacitidine in a Series of 94 Patients with Chronic Myelomonocytic Leukemia from the Spanish Group of Myelodysplastic Syndromes. (April 2017)

4. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. (May 2022)

5. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF GERIATRIC ASSESSMENT AND SOMATIC MUTATIONS IN HIGH-RISK MYELODYSPLASTIC SYNDROMES NOT ELIGIBLE FOR ALO-HCST. CET-AZA-2016–1 2022 UPDATE. ON BEHALF OF THE CETLAM GROUP. (May 2023)